Recombinant Human LAR Protein

Catalog # Availability Size / Price Qty
9377-PF-050
Recombinant Human LAR Protein Bioactivity
1 Image
Product Details
FAQs
Supplemental Products
Reviews

Recombinant Human LAR Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Recombinant Human LRFN5 Fc Chimera (Catalog # 9385-SA) is used at 1 μg/mL, the concentration of Recombinant Human LAR that produces 50% optimal binding response is 1.5-9 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human LAR protein
Ala27-Glu1251 with a C-terminal 6-His tag, and its proteolyzed forms Ala27-Arg1169 and Gln1170-Glu1251 with a C-terminal 6-His tag
Accession #
N-terminal Sequence
Analysis
Ala27 and Gln1170
Predicted Molecular Mass
136 kDa
SDS-PAGE
114-146 kDa and 14 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9377-PF

Formulation Supplied as a 0.2  μm filtered solution in PBS.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Data Image

Bioactivity Recombinant Human LAR Protein Bioactivity View Larger

When Recombinant Human LRFN5 Fc Chimera (Catalog # 9385-SA) is used at 1 µg/mL, 100 µL/well, Recombinant Human LAR (Catalog # 9377-PF) binds with an ED50 of 1.5-9 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: LAR

PTPRF (Receptor-type tyrosine-protein phosphatase F), also called LAR (Leukocyte common antigen related), is a 212 kDa single-pass type I membrane protein that is a member of the protein tyrosine phosphatase (PTP) family and the receptor class 2A subfamily (1). Human LAR cDNA encodes 1,907 amino acids (aa) including a 29 aa signal sequence, a 1234 aa extracellular region with six potential N-glycosylation sites, a 21 aa transmembrane sequence, and a 623 aa cytoplasmic domain (1). An 1,898 aa isoform appears from alternative splicing; it is missing aa 772 to 780 (1). Human LAR shares a 95% aa sequence identity with mouse and rat LAR. LARs have been shown to function in the regulation of epithelial cell-cell contacts at adherents junctions, as well as in the control of beta-catenin signaling (2). An increased expression level of LARs have been found in the insulin-responsive tissue of obese, insulin-resistant individuals, and may contribute to the pathogenesis of insulin resistance (3). LARs have been identified as novel ligands of SALM5/LRFN-5 that mediates SALM5/LRFN-5 dependent presynaptic differentiation in a splicing- dependent manner. SALM5/LRFN-5 interacts directly with the Ig domain of LAR family receptor protein tyrosine phosphatases. The postsynaptic SALM5/LRFN-5 promotes synapse development by trans-synaptically interacting with presynaptic LARs which is important for the regulation of excitatory synaptic strength (4). Clinically, LAR has been shown down-regulated in cancers and its up-regulation is associated with better clinical outcomes (5).

References
  1. SwissProt Accession # P10586.
  2. Um J.W. et al. (2013) Trends Cell Biol. 23:465.
  3. Mander A. et al. (2005) FEBS Lett. 579:3024.
  4. Choi, Y. et al. (2016) Sci Rep. 6:26676.
  5. Bera, R. et al. (2014) Hepatology. 59:2238.
Long Name
Leukocyte Antigen-Related Tyrosine Phosphatase
Entrez Gene IDs
5792 (Human); 104121 (Mouse)
Alternate Names
LAR; LCA-homolog; protein tyrosine phosphatase, receptor type, F; PTPRF; receptor type, F polypeptide; receptor-linked protein-tyrosine phosphatase LAR; receptor-type tyrosine-protein phosphatase F

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reconstitution Buffers

Reviews for Recombinant Human LAR Protein

There are currently no reviews for this product. Be the first to review Recombinant Human LAR Protein and earn rewards!

Have you used Recombinant Human LAR Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review